Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
236. |
ECCT/24/02/04 | IGHID 12333 IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya. |
Principal Investigator(s) 1. Chemtai Mungo Site(s) in Kenya Lumumba subcounty Hospital Kisumu |
View |
237. |
ECCT/24/07/01 | LCCC 2330 Feasibility of intravaginal artesunate as adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: A Phase II trial |
Principal Investigator(s) 1. Chemtai Mungo Site(s) in Kenya Cervical Cancer Screening Program (CCSP) Lumumba Sub-County Hospital |
View |
238. |
ECCT/22/11/04 | YWF:03 YWF:03: A PHASE III, MULTICENTER, DOUBLE BLIND, RANDOMIZED STUDY OF SII YELLOW FEVER VACCINE TO COMPARE SAFETY AND IMMUNOGENICITY WITH STAMARIL® |
Principal Investigator(s) 1. Videlis Nduba 2. Otieno Walter Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
239. |
ECCT/23/05/04 | PRIORITY Trial Prevention of Iron Deficiency Anemia Post-delivery |
Principal Investigator(s) 1. FABIAN OMODING ESAMAI 2. PAUL OBANDA NYONGESA Site(s) in Kenya BUSIA COUNTY REFERRAL HOSPITAL |
View |
240. |
ECCT/22/03/02 | MOVe AHEAD STUDY A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19 |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI RCTP KISUMU |
View |